Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
10,822,351
-
Share change
-
-1,258,888
-
Total reported value
-
$2,486,573
-
Put/Call ratio
-
19%
-
Price per share
-
$0.23
-
Number of holders
-
33
-
Value change
-
-$330,765
-
Number of buys
-
7
-
Number of sells
-
21
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q3 2024
As of 30 Sep 2024,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
33 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,822,351 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock, Inc., LIBERTY WEALTH MANAGEMENT LLC, Weaver Consulting Group, STATE STREET CORP, NORTHERN TRUST CORP, RAYMOND JAMES & ASSOCIATES, and JMAC ENTERPRISES LLC.
This page lists
33
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.